SITAGLIPTIN » NIMS

Generic Index

SITAGLIPTIN ( SYE-ta-GLIP-tin )

INDICATIONS

Adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus as monotherapy or as combination therapy.

DOSES

Adults: PO 100 mg once daily.

Renal Function Impairment

Adults:

Moderate renal impairment (CrCl 30 to less than 50 mL/min): PO 50 mg once daily.

Severe renal impairment (CrCl less than 30 mL/min) or ESRD requiring hemodialysis or peritoneal dialysis: PO 25 mg once daily. Administer without regard to the timing of hemodialysis.

•		May be taken with or without food.
•		When used in combination with a sulfonylurea, a lower dose of the sulfonylurea may be required to reduce the risk of hypoglycemia.

MECHANISM OF ACTION

Sitagliptin is a dipeptidyl peptidase-4 inhibitor that is thought to act in type 2 diabetes by slowing the inactivation of incretin hormones.

CONTRAINDICATIONS/ PRECAUTIONS

•		Insulin dependent diabetes mellitus.
•		Diabetic ketoacidosis.
•		Hypersensitivity.

CNS: Headache (1%).
EENT: Nasopharyngitis (5%).
GI: Diarrhea (3%); abdominal pain (2%); nausea (1%); acute pancreatitis, hepatic enzyme elevations (postmarketing).
HYPERSEN: Hypersensitivity reactions, including anaphylaxis, angioedema, cutaneous vasculitis, exfoliative skin conditions (including Stevens-Johnson syndrome), rash, and urticaria (postmarketing)
RESP: Upper respiratory tract infection (5%).

INTERACTIONS

Cyclosporine

Sitagliptin plasma concentrations may be increased modestly (approximately 68%), which is not expected to be clinically important.

Digoxin

Digoxin plasma concentrations may be increased slightly (approximately 18%); no dosage adjustment is recommended.

Sulfonylurea (eg, tolbutamide)

A lower dose of the sulfonylurea may be needed to reduce the risk of hypoglycemia.

CLASSIFICATION

Therapeutic Classification: antidiabetics

Pharmacologic Classification: enzyme inhibitors

PHARMACOKINETIC

Absorption: 87% absorbed following oral administration.

Distribution: Unknown.

Metabolism/Excretion: 79% excreted unchanged in urine, minor metabolism.

Half-life: 12.4 hr.

TIME/ ACTION

ROUTE	ONSET	PEAK	DURATION
ORAL	RAPID	1-4 HOUR	24 HOUR

Brand Drugs in Nepal

GLIPITA BEXIMCO
SITAGLIP DJPL(suswasthya)
SIGLIP ALIVE
MYSITAG SUMY
JANVI VIJAYADEEP(saicard)
INSUGLIP S.R.
GLIPTIN
GLIPSI NATIONAL(spt)

Generic Index

SITAGLIPTIN ( SYE-ta-GLIP-tin )

INDICATIONS

DOSES

MECHANISM OF ACTION

CONTRAINDICATIONS/ PRECAUTIONS

ADVERSE EFFECT

INTERACTIONS

CLASSIFICATION

PHARMACOKINETIC

TIME/ ACTION

Brand Drugs in Nepal

Combined Drug

Support

About Us

Terms & Privacy

Connect with us